BHCM
SABS icon

Brevan Howard Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Brevan Howard Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Buy
+59,161
New +$236K ﹤0.01% 1819

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Brevan Howard Capital Management's SABS Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 59,161 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #1819 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Brevan Howard Capital Management held 59,161 shares of SAB Biotherapeutics worth $227K as of Q1 2026.
  • SAB Biotherapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1819 holding.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.